Double Helix Biotechnology Dev. has been acquired by Interpublic Group of Companies
Double Helix Bio-Technology Development Ltd. (Double Helix), a leading, global provider of market research and market access services to the pharmaceutical and medical device industries, has been sold to McCann Health, owned by The Interpublic Group of Companies Inc. Financial details of this transaction have not been disclosed.
Founded by Dr Wayne Phillips and based in London, Double Helix not only specializes in the established markets of the US and Europe, but also focuses on emerging markets, providing clients with a truly global perspective. In the past year, Double Helix has performed projects across more than 40 countries for over 30 major pharmaceutical multinational clients. Dr Phillips will continue as CEO of Double Helix, reporting to John Cahill, CEO of McCann Health.
McCann Health is a part of McCann Worldgroup, the largest marketing communications agency network in the world, and is a leading healthcare agency network owned by The Interpublic Group of Companies Inc.
Oaklins Cavendish, based in the UK, acted as financial advisor to the seller.
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
GroupTalk has been acquired by AddSecure
The private shareholders of GroupTalk have sold the company to AddSecure, a leading European provider of secure IoT connectivity and end-to-end solutions. This acquisition supports AddSecure’s strategic goal of expanding its offering in secure critical communications.
Learn moreRindegastos has been acquired by Visma
Rindegastos S.p.A. has been acquired by Visma. The transaction involved the sale of 100% of the company, with 60% of the shares transferred at closing and the remaining shares to be sold through deferred payments, contingent on Rindegastos’ future performance. This structure aims to align incentives around the company’s continued growth and expansion, ensuring a change of control that reflects Rindegastos’ long-term vision and expectations.
Learn moreCerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn more